View Post

G-CSF Cuts Febrile Neutropenia Rates in Early Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Liam Davenport From: Women with early-stage breast cancer had a significantly lower rate of febrile neutropenia when given granulocyte-colony stimulating factors (G-CSF) alongside their chemotherapy rather than the antibiotic ciprofloxacin, indicate new data from a randomized trial. The research was presented at the 2020 annual meeting of the American Society of Clinical Oncology, held virtually because of the …

View Post

Five Days of G-CSF Adequate for Breast Cancer Chemo

In In The News by Barbara Jacoby

fiBy: Charles Bankhead, Senior Editor From: Five days of prophylactic granulocyte colony-stimulating factor (G-CSF) proved as effective as 7 to 10 days for preventing chemotherapy-induced febrile neutropenia in patients with early breast cancer, a randomized trial showed. Patients assigned to the 5-day regimen of filgrastim (Neupogen) had a 2.09% incidence of febrile neutropenia or treatment-related hospitalization per cycle of …